Skip to main contentAI and Advanced
/
WANBURY · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
WA
NSE · Equity shares · Biotechnology & Drugs1.20 · 0.54%
Wanbury WANBURY
NSE:INR 224.3
BSE:INR 223.2
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for WANBURY
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 223.1
Day rangeINR 219 — INR 229.3
52-week rangeINR 161.5 — INR 360
Volume1.61 L
Market cap1,166.97
P/E10.8
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)650.27
Net Income (INR Cr)66.13
Rev Growth (5 Year %)10.62
P/E Ratio10.8
Book Value40.57
EPS21.21
Price/BV5.53Computed
Research path: Interpret Wanbury's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
WANBURYWanbury1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 517.67 | 413.92 | 343.49 |
| Cash Equivalents | 6.02 | 0.34 | Not available |
| Other Liabilities Total | 22.83 | 18.92 | 15.51 |
| Long Term Debt | 147.15 | 160.29 | 82 |
| Common Stock Total | 34.94 | 32.77 | 32.75 |
| Other Current Assets Total | 34.32 | 8.35 | 2.5 |
| Total Assets | 517.67 | 413.92 | 343.49 |
| Current Portof LT Debt/Capital Leases | 75.01 | 11.64 | 15.6 |
| Cash | 1.61 | 4.48 | 3.4 |
| Total Equity | 144.45 | 59.27 | 27.94 |
| Long Term Investments | 3.98 | 0.02 | 0.03 |
| Retained Earnings(Accumulated Deficit) | 109.51 | -82.3 | -113.47 |
| Total Common Shares Outstanding | 3.49 | 3.28 | 3.27 |
| Tangible Book Valueper Share Common Eq | 40.57 | 18.02 | 8.45 |
| Total Liabilities | 373.22 | 354.65 | 315.55 |
| Total Debt | 224.37 | 176.91 | 116.48 |
| Short Term Investments | 2.7 | 0.13 | Not available |
| Cashand Short Term Investments | 10.33 | 4.96 | 3.4 |
| Total Receivables Net | 143.28 | 140.43 | 111.63 |
| Accounts Receivable-Trade Net | 143.28 | 114.3 | 89.55 |
| Property/Plant/Equipment Total-Net | 251.94 | 205.76 | 169.56 |
| Total Current Liabilities | 201.04 | 174.61 | 214.11 |
| Total Inventory | 50.63 | 37.68 | 36.02 |
| Accounts Payable | 107.25 | 138.46 | 162.75 |
| Other Currentliabilities Total | 18.78 | 12.25 | 13.32 |
| Total Long Term Debt | 149.36 | 161.11 | 85.93 |
| Intangibles Net | 2.71 | 0.23 | 0.27 |
| Other Long Term Assets Total | 14.2 | 11.07 | 12.34 |
| Note Receivable-Long Term | 6.28 | 3.4 | 2.01 |
| Total Current Assets | 238.56 | 193.44 | 159.29 |
| Capital Lease Obligations | 2.21 | 0.82 | 3.93 |
| Accumulated Depreciation Total | Not available | -90.78 | -80.31 |
| Accrued Expenses | Not available | 8.09 | 7.48 |
| Other Equity Total | Not available | 0.17 | 0.17 |
| Prepaid Expenses | Not available | 2.03 | 5.73 |
| Additional Paid-In Capital | Not available | 108.62 | 108.5 |
| Property/Plant/Equipment Total-Gross | Not available | 291.16 | 246.87 |
| Notes Payable/Short Term Debt | Not available | 4.16 | 14.95 |
| Unrealized Gain(Loss) | Not available | 0.01 | 0 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %10.62
Margins
Operating Margin 12m13.66
Operating Margin 5y Avg12.3
Net Profit Margin 12m10.17
Net Profit Margin 5y7.89
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio1.79
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk61.89
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,938.4 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,366.95 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,972.75 | 1.68 L | 72.73 | — |
| Cipla | INR 1,409.1 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,121.5 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 43.02%
- FII
- 0.89%
- Other
- 56.09%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Corporate actions
Events
- board Meetings(Revised)
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- annual General MeetingEGM
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
Rusaka Markets Community
Discussion and sentiment for Wanbury
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Wanbury Limited is an India-based pharmaceutical company with a presence in the active pharmaceutical ingredients (APIs) global market and domestic branded formulations. The Company is engaged in the business of pharmaceutical and related activities, including research. Its API products include Metformin, Metformin Dc, Tramadol, Sertraline, Diphenhydramine HCL, Diphenhydramine Citrate, Mefenamic Acid, Paroxetine Hemihydrate, Promethazine, Glucosamine, Clopidogrel, Levetiracetam and Carvedilol Phosphate Monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on the development of products like ketamine, rivaroxaban, montelukast, sitagliptin and a few others to reduce dependency on metformin and sertraline. The Company has facilities in Tanuku, Andra Pradesh, and Patalganga, Maharashtra.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- WANBURY
- BSE Code
- 524212
Questions
Stock FAQ
What is the symbol and ISIN of Wanbury?
Wanbury has the symbol WANBURY and ISIN - INE107F01022.
What is the current price of Wanbury?
Wanbury is currently trading at INR 224.30.
What are the year high and year low of Wanbury?
Wanbury has a year high of INR 360.00 and a year low of INR 161.50.
What is the market capitalization of Wanbury?
Wanbury has a market capitalization of INR 1,166.97 crore.
What is the P/E ratio of Wanbury?
Wanbury has a P/E ratio of 10.80.
What is the dividend yield of Wanbury?
Wanbury has a dividend yield of 0.00%.
How is the financial performance of Wanbury based on revenue, net income, and EPS?
Wanbury has revenue of INR 650.27 crore, net income of INR 66.13 crore, and EPS of INR 21.08.
What is the book value of Wanbury?
Wanbury has a book value of INR 40.57.
What is the debt-to-equity ratio of Wanbury?
Wanbury has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Wanbury?
Wanbury has a price-to-book ratio of 5.53 and a price-to-sales ratio of 1.79.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.